Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 11, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 69 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ventilator-acquired Pneumonia Clear all
Active, not recruiting Not applicable Interventional

Frequent Standardized Oral Care to Improve Health Outcomes in Premature Infants in the Neonatal Intensive Care Unit

NCT05167318
View directory record Official record
Conditions
Microbial Colonization, Ventilator Associated Pneumonia
Interventions
frequent standardized oral care
Other
Lead sponsor
University of Florida
Other
Eligibility
12 Hours to 72 Hours
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

NCT02714595
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Best Available Therapy
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Hartford, Connecticut • Newark, Delaware • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Not applicable Interventional

Oropharyngeal Administration of Mother's Colostrum for Premature Infants (NS-72393-360)

NCT02116699
View directory record Official record
Conditions
Infection, Enterocolitis, Necrotizing, Ventilator-associated Pneumonia
Interventions
oropharyngeal mother's milk, oropharyngeal sterile water
Other
Lead sponsor
Endeavor Health
Other
Eligibility
1 Day to 4 Days
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
5
States / cities
Miami, Florida • Evanston, Illinois • Park Ridge, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2023 · Synced Jun 11, 2026, 5:09 AM EDT
Completed No phase listed Observational

Multidrug Resistant Gram-negative Bacilli Colonization and Infection in Burn

NCT02653157
View directory record Official record
Conditions
Multi-drug Resistant Gram-negative Bacilli Colonization
Interventions
MDR-GNB
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2018 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults

NCT02168946
View directory record Official record
Conditions
Urinary Tract Infection Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia, Abdominal Infection
Interventions
Vabomere, Best Available Therapy
Drug
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
20
States / cities
Hartford, Connecticut • Tampa, Florida • Augusta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants

NCT06086626
View directory record Official record
Conditions
Gram-Negative Bacterial Infections
Interventions
Cefiderocol, Standard of Care
Drug
Lead sponsor
Shionogi
Industry
Eligibility
Up to 3 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
Little Rock, Arkansas • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Endotracheal Tubes to Prevent Ventilator-Associated Pneumonia

NCT03705286
View directory record Official record
Conditions
Ventilator-acquired Pneumonia
Interventions
EVAC-PU-ETT, PVC-ETT
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
1,074 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Jun 11, 2026, 5:09 AM EDT
Not listed No phase listed Observational

Airway Microbiome Changes After Artificial Airway Exchange in Critically-ill Pediatric Patients.

NCT06201130
View directory record Official record
Conditions
Tracheostomy, Endotracheal Tube, Ventilator Associated Pneumonia, Tracheitis, Microbial Colonization, Pediatric Infectious Disease, Pediatrics
Interventions
Suctioning of artificial airway
Diagnostic Test
Lead sponsor
Northwell Health
Other
Eligibility
0 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Queens, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 4 Interventional

Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial

NCT02462590
View directory record Official record
Conditions
Ventilator Associated Pneumonia, Infections, C-Difficile, Antibiotic-associated Diarrhea, Diarrhea
Interventions
L. rhamnosus GG - Probiotic, Placebo - Microcrystalline Cellulose
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
2,650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 16, 2020 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

NCT04215991
View directory record Official record
Conditions
Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP), Complicated Urinary Tract Infection (cUTI), Ventilator Associated Bacterial Pneumonia (VABP)
Interventions
Cefiderocol, Standard of Care
Drug
Lead sponsor
Shionogi
Industry
Eligibility
3 Months to 17 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Iowa City, Iowa • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

Effect of Improved Oral Hygiene to Prevent Pneumonia in Hospitalized Patients

NCT00123123
View directory record Official record
Conditions
Pneumonia
Interventions
chlorhexidine gluconate oral rinse (0.12%), placebo
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 4, 2021 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

Lactobacillus GG in the Prophylaxis of Ventilator Associated Pneumonia

NCT00613795
View directory record Official record
Conditions
Pneumonia, Ventilator Associated Pneumonia
Interventions
Lactobacillus GG, placebo
Dietary Supplement
Lead sponsor
Creighton University
Other
Eligibility
19 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 17, 2010 · Synced Jun 11, 2026, 5:09 AM EDT
Terminated Phase 3 Interventional Results available

Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia

NCT01853982
View directory record Official record
Conditions
Ventilator-Associated Pneumonia (VAP)
Interventions
Ceftolozane/Tazobactam, Piperacillin/Tazobactam
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
11
States / cities
Jacksonville, Florida • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Jun 11, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional

Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit

NCT06000761
View directory record Official record
Conditions
Ventilator Associated Pneumonia, Bronchopulmonary Dysplasia, Respiratory Disease
Interventions
Standardized oral Care
Procedure
Lead sponsor
University of Florida
Other
Eligibility
1 Hour to 3 Days
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Not applicable Interventional Results available

Ventilator-associated Pneumonia (VAP) Diagnostic Stewardship Trial

NCT05176353
View directory record Official record
Conditions
VAP - Ventilator Associated Pneumonia
Interventions
VAP diagnostic stewardship bundle
Other
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
4,892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Jun 11, 2026, 5:09 AM EDT
Completed No phase listed Observational

Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae

NCT02420366
View directory record Official record
Conditions
Urinary Tract Infection, Complicated, Acute Pyelonephritis, Hospital Acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia, Bacteremia
Interventions
Not listed
Lead sponsor
Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Chicago, Illinois • Evanston, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Jun 11, 2026, 5:09 AM EDT
Terminated Not applicable Interventional

Serial, Non-invasive Analysis of Exhaled Breath Condensate in Ventilated Trauma Patients

NCT02652247
View directory record Official record
Conditions
Ventilator Associated Pneumonia (VAP)
Interventions
molecular analysis of exhaled breath condensate, molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate, molecular analysis of bronchoalveolar lavage (BAL) aspirate
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Jun 11, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional

Macrophage Programing in Acute Lung Injury: MiniBAL

NCT05767671
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Ventilator Associated Pneumonia
Interventions
Non-Bronchoscopic Mini Bronchoalveolar Lavage
Other
Lead sponsor
William Janssen, MD
Other
Eligibility
18 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jun 11, 2026, 5:09 AM EDT
Terminated Phase 4 Interventional Results available

The Duration of Antibiotic Therapy for Early (DATE) Ventilator Associated Pneumonia (VAP): 4 vs. 7 Days

NCT05545735
View directory record Official record
Conditions
Ventilator Associated Pneumonia
Interventions
Standard of Care Antibiotic Therapy
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

Silver-Coated Endotracheal Tube to Reduce Ventilator Associated Pneumonia (VAP)

NCT00148642
View directory record Official record
Conditions
Respiratory Failure
Interventions
silver salts coated endotracheal tube, uncoated endotracheal tube
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
2,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
5
States / cities
San Diego, California • Oak Park, Illinois • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Jun 11, 2026, 5:09 AM EDT
Completed No phase listed Observational

Study of Knowledge Translation of Clinical Practice Guidelines for Ventilator Associated Pneumonia

NCT00434460
View directory record Official record
Conditions
Ventilator Associated Pneumonia
Interventions
Education
Behavioral
Lead sponsor
Canadian Critical Care Trials Group
Other
Eligibility
17 Years and older
Enrollment
1,320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2010 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

Ventilator-Associated Pneumonia/Hospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support

NCT00050401
View directory record Official record
Conditions
Pneumonia
Interventions
MERREM I.V. 2g as a 3 hour infusion every 8 hours, vancomycin I.V. 1 g every 12 hours, tobramycin I.V. 5 mg/kg every 24 hours, MERREM I.V. 1g as a 30 minute infusion every 8 hours, MERREM I.V. 500 mg as a 3 hour infusion every 8 hours
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
10
States / cities
Phoenix, Arizona • Newark, Delaware • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Jun 11, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Safety and Efficacy of Tigecycline Versus Imipenem/Cilastatin Subjects With Hospital-Acquired Pneumonia

NCT00707239
View directory record Official record
Conditions
Pneumonia, Bacterial
Interventions
tigecycline, imipenem/cilastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Louisville, Kentucky • Omaha, Nebraska • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Jun 11, 2026, 5:09 AM EDT
Completed Phase 3 Interventional Results available

Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

NCT03032380
View directory record Official record
Conditions
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
Interventions
Cefiderocol, Meropenem, Linezolid
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
15
States / cities
New Haven, Connecticut • DeLand, Florida • Chicago, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Jun 11, 2026, 5:09 AM EDT